SlideShare una empresa de Scribd logo
1 de 59
The Menopause
Management Workshop
Menopause
H.R.T.
Moderator :- DR. SHARDA JAIN
Dr. Sharda Jain
MD(PGIMER), MNAMS, FICOG
FIMSA, DHM,QM & AHO
Director :-
Sec General : Delhi Gynae Forum
How
To
Handle
M
E
N
O
P
A
U
S
E
We all are Confused
In Last 15 years - this is my 15th
presentation
PRESENTATION is an ART , Not a science .
Which means It's Never perfect and can always improve.
Customer’s Place
Most Unhappy
Customer – learing
Put your self in a customer’s place
Most unhappy customer are
greatest source of learning
Menopause
 Menopause marks the end of
reproductive capacity of
women and results from the
permanent cessation of
ovarian function
 The median age for the onset of
menopause: 51.4 years
 Indian Context: 40.32–48.84
years
 By 2015, about 130 million
Indian women are expected to
live beyond menopause
Menopausal transition
Xu J, et al. J Am Board Fam Pract. 2005;18:374–382.
Umland ME. J Manag Care Pharm. 2008;14(3)(suppl S):S14–S19.
Sharma S, et al. JK Sci. 2007;9(1):13–17.
Aarti K. J Obst Gynecol India. 2011;323–326.
Menopause
Long Term Effects
Symptoms
Vasomotor Urogenital Mood /Cognitive
Osteoporosis Poor Bowel / Bladder Vision
H. Dis. Skin M.Tone
Complaints % western
women
West India North
India
Irritability 92 48 36
Lethargy 88 45 -
Depression 78 43 10
Flushes and night sweats 75 38 22
Headaches 64 27 15
Forgetfulness 61 60 65
Weight gain insomnia 51 60 70
How Common Are the various menopause symptoms
Relative frequency of climacteric
Symptoms in India
Symptoms India Incidence
Anklesaria
1995
Krishna
1995
Hot Flashes 30% 33%
Urinary Complaints 74% 35%
Vaginal Symptoms 56% 50%
Joint/ Muscle pain 20% 25%
Psychological 36% 20%
Treatmentof
Menopause
after
WHI
is never the same
WHI
Myths
Principles
•Time – Shortest possible
•Dose – Smallest possible
•Counseling – All short & long term risks
is mandatory
of HT
Redefining
TIBOLONE
in menopause
Structure and Mechanism of Action
 Tibolone is a selective tissue
oestrogenic activity regulator.
 Tibolone substitutes for the
loss of oestrogen production in
postmenopausal women, and
alleviates menopausal
symptoms.
 Tibolone prevents bone loss
following menopause or
ovariectomy
1960/70
Steckelbroeck S, et al. Mol Pharmacol.2004;66: 1702–1711.
Tibolone summary of product characteristics. Available at: www.medicines.org.uk.
Specific binding affinities of
tibolone and its primary metabolites
Tissue-Specific Effects of
Tibolone’s Metabolites
Modelska K, et al. J Clin Endocrinol Metab. 2002;87(1):16–23.
Palacios S. Eur Heart J Supplements. 2001; 3 (Suppl M): M12–M16.
+: Stimulatory effect;-: Suppressive effect; ?:
Unknown effect
Tissue-Specific Effects of Treatment Modalities
for Menopause: The Tibolone Edge
Tibolone Estrogen Estrogen+
progesterone
Raloxifene
(SERM)
Bone (BMD) + + + +
Climacteric symptoms + + + -
Vagina + - - +
Mood & libido ++ =/+ = =
Endometrium = - - =
Breast pain & density = - - =
Breast cancer = - - =/+
Venous thromboembolism = - - -
Myocardial infarction/stroke = - - =
STEAR: Selective, tissue estrogenic activity regulator ; SERMs: Selective estrogen receptor modulator.
+: Positive (beneficial effect); =: Neutral effect; -: Negative (detrimental) effect
Kloosterboer HJ. J Steroid Biochem Mol Biol.2003;83: 157–165.
The clinical profile of tibolone has advantages over
other treatment modalities
Effect of Tibolone on
Vasomotor and Urogenital
Symptoms of Menopause
Summary of Comparison of
Tibolone with Combine HT
Assessment
parameters
Tibolone vs. estrogen+progesterone HT
Vasomotor
symptoms
Comparable and significant reduction
inhot flashes, sweating and vaginal
dryness.
Better improvement in dryness of
skin with tibolone
Hot flushes: tibolone versus CHT (Comparable)
Baracat et al.Climacteric 2002
Control of vasomotor symptoms
*Significantly different from baseline; CEE, conjugated
equine estrogens; MPA, medroxyprogesterone acetate
Meanvalue
14
12
10
8
6
4
2
0
Baseline 3 6 9 13
*
* * * * * * *
Tibolone (n = 40)
CEE/MPA (n = 45)
Hot flushes
Treatment cycle
Clinical Evidence 1:
Tolerability Trial comparing
Livial vs E2 / NETA
Objective: To compare the efficacy and safety of tibolone vs. low-dose continuous combined
estradiol plus norethisterone acetate (E2/NETA) in healthy symptomatic postmenopausal
women (age: 45–65 years) (n=572).
Study Endpoints: Prevalence of vaginal bleeding, hot flushes and adverse events.
Study Results
 Comparable reductions in vasomotor symptoms
and vaginal atrophy in both the groups.
 Significantly lower incidence of vaginal bleeding
and breast pain/tenderness in the tibolone group.
Conclusion: Tibolone produced effective and
comparable reduction in menopausal
symptoms, and was associated with a lower
incidence of vaginal bleeding and breast
pain/tenderness vs. E2/NETA.
Hammar ML, et al. BJOG. 2007;114(12):1522–1529.
Tibolone
V/S HT
Urogenital
symptoms
Significantly lower incidence and
recurrence of vaginal bleeding/spotting
Significant improvement of lower vaginal
tract symptoms
Improvement in vaginal cytology
Clinical Evidence 2:
Long-Term Effects of Tibolone
on Urogenital Symptoms
Objective: To evaluate the effects of six years of tibolone therapy on the genital tract in
postmenopausal women (n=113).
Study Endpoints: Assessment of urogenital symptoms, vaginal epithelial activity and calculation of
vaginal karyopyknotic index and maturation index.
Study Results
 Significant improvement in the lower genital tract
symptoms in comparison to control.
 Significant increase in the karyopyknotic index and
maturation index in the tibolone group.
 Improvement in vaginal symptomatology with
minimal endometrial stimulation.
Conclusion: Tibolone was effective at
maintaining an inactive endometrium while
providing oestrogenisation of the lower
genital tract.
Morris EP, et al. Br J Obstet Gynaecol. 1999;106(9):954–959.
Assessment
parameters Tibolone vs.
Estrogen+progesterone (E+P) Raloxifene
Bone
Significantly greater increase in
lumbar spine, trochanter and total
hip BMD with tibolone
Significantly
greater increase
in lumbar spine
and total hip
BMD with
tibolone
Tibolone V/S HT (E + P) & Raloxifene
BONE
Clinical Evidence 1:
Study of Tibolone V/s raloxifene
Effects on osteoPenia (STEP)
Objective: To compare the efficacy of tibolone vs. raloxifene on BMD of the lumbar spine and
hip in osteopenic postmenopausal women (n=308).
Endpoints: Measurement of BMD, serum osteocalcin and serum type I collagen C-telopeptides
Study Results
 Larger increase in lumbar spine BMD after 1- and 2-
years and total hip BMD after 2 years of therapy
with tibolone vs. raloxifene.
 Comparable reductions in serum osteocalcin and
serum type I collagen C-telopeptides .
Conclusion: Tibolone prevented postmenopausal bone loss in older women and resulted in a
larger increase of BMD both at the lumbar spine and hip than raloxifene
Delmas PD, et al. Osteoporos Int. 2008;19(8):1153–
1160.
Tibolone vs.
raloxifene
p<0.01 for lumbar
BMD (1 y)
p<0.001 for lumbar
BMD (2 y)
p<0.05 for total hip
BMD (2 y)
Clinical Evidence 2: Long-term
Intervention on Fractures with
Tibolone (LIFT)
Objective: To assess the efficacy of tibolone in preventing bone loss and its effects on
fractures, breast cancer and cardiovascular disease.
Endpoints: Assessment of vertebral fractures and rates of cardiovascular disease and breast
cancer.
Study Results
 Increase in BMD of the spine and femoral neck in the
tibolone group.
 Decreased risk of vertebral and non-vertebral fractures
with tibolone.
 Decreased risk of invasive breast cancer and colon cancer
with tibolone therapy.
 Increased risk of stroke, but no difference in the risk of
coronary heart disease or venous thromboembolism with
tibolone vs. placebo.
Conclusion: Tibolone reduced the risk of fracture and breast cancer and possibly colon
cancer in older women with osteoporosis.
B Cummings SR, et al. N Engl J Med. 2008;359(7):697–708.
Summary of Effects of
Tibolone V/S HRT
SEXUAL
HEALTH
Improvement in sexual health and loss of
libido
Increased sexual frequency, satisfaction
and enjoyment
Significant reduction in SHBG
Increase in free testosterone levels
MOOD Improvement in mood
Clinical Evidence 2: Efficacy of Tibolone
vs. Conventional HRT on Sexual
Function
Objective: To compare the effects of TIBOLONE VS. CONVENTIONAL HORMONE
REPLACEMENT THERAPY on climacteric symptoms and sexual function in
postmenopausal women (n=140).
Endpoints: Evaluation of the GCS questionnaire and Rosen's FSFI. Measurement of
SHBG, FEI and FTI. Follow-up period: 6 months.
Study Results
 Comparable improvement in climacteric
symptoms.
 Greater improvement in the sexual subscore of
GCS in the tibolone group.
 Greater improvement in the desire, arousal and
orgasm sexual domains of the FSFI in the tibolone
group
 Greater and significant reduction in SHBG and
increase in FEI and FTI in the tibolone group.
Conclusion: Tibolone was found to be an effective alternative to conventional
HRT in the treatment of climacteric symptoms and sexual dysfunction in
postmenopausal women. Ziaei S, et al. Climacteric. 2010;13(2):147–156.
p<0.001 for tibolone vs.
CEE/MPA and control
ENDOMETRIUM
NO DIFFERENCE IN THE INCIDENCE
OF PROLIFERATION, ENDOMETRIAL
HYPERPLASIA OR CANCER
MORE FREQUENT AMENORRHEA
WITH TIBOLONE
Summary of Comparison of
Tibolone with
HRT ( E2/ NETA)
Clinical Evidence 1:
Tibolone v/S HRT
Histology on the Endometrium and Breast
Endpoints Study (THEBES)
Objective: To compare the endometrial safety of tibolone vs. CEE/MPA in healthy
postmenopausal women (n=3240)
Endpoints: Evaluation of the incidence of abnormal endometrial histology (hyperplasia or
carcinoma) and hyperplasia and carcinoma after 1 and 2 years of treatment.
Study Results
 No endometrial hyperplasia in the tibolone group.
 More frequent amenorrhea was reported with tibolone
1.25 mg (78.7%) and 2.5 mg (71.4%) than CEE/MPA
(44.9%).
 Low incidence of breast pain in the tibolone group.
Conclusion: Tibolone did not induce endometrial hyperplasia or carcinoma in
post-menopausal women, and was associated with a better vaginal bleeding
profile than CEE/MPA.
Archer DF, et al. J Clin Endocrinol Metab. 2007;92(3):911–918.
Key Take Home Messages—
Tibolone
Breast Cancer
Breast
Cancer
Effective in symptomatic
breast cancer patients,
with improvement in
quality of life*
Tibolone
&
Breast pain and density
Breast
pain &
density
Lower incidence/decrease in breast
pain/tenderness/mastalgia
No increase in mammographic density
of breast
Decrease in breast density scores
Decreased expression of
immunohistochemical markers
Tibolone Does Not Increase the
Mammographic Breast Density
Lundström E, et al. Am J Obstet Gynecol. 2002;186(4):717–722.
Clinical Evidence: Tibolone vs. 17β-Estradiol
in SURGICAL MENOPAUSE
Objective: To compare the effectiveness of tibolone and 17β-estradiol on climacteric symptoms
in surgically menopausal women (n=40)
Endpoints: Assessment of climacteric symptoms with Greene Climacteric Scale at baseline,
during washout and after the treatments.
Study Results
 Significant improvement from baseline in all
the subscale scores in both study groups.
 Improvement in psychological, somatic and
sexual subscales was significantly superior
in the tibolone group.
 Comparable relief of vasomotor symptoms
in both groups
Conclusion: Tibolone may improve mood, libido and somatic symptoms in surgically menopausal
women to a greater extent than estrogen therapy alone.
Somunkiran A, et al. Maturitas. 2007;56(1):61–68.
Clinical Evidence:
Effect of Tibolone on
Health-Related Quality of Life
Objective: To assess the improvements in HRQOL in menopausal women using tibolone
(n=100).
Endpoints: Assessment of change in HRQOL after 3 and 12 months of treatment.
Study Results
 Significant improvement in HRQOL
after 3 and 12 months of treatment
with tibolone.
 Maximal improvement was observed
in the somatovegetative subscale.
Conclusion: Tibolone was found to be effective in improving the overall HRQOL of
menopausal women. Somatovegetative symptoms showed most improvement.
Bhattacharya SM. Int J Gynaecol Obstet. 2007;99(1):43–45.
Somatoveget
ative
complaints
Psycholo
gical
complain
ts
Urogenita
l
complaint
s
Baseline 9.9 12.2 7
After 3
months
5.3 5 2.9
After 12
months
3.8 4.4 2.4
Golden Tips
Huang K-E, et al. Climacteric. 2010;13:317–327.
Key Take Home Messages—
Summary of Effects of Tibolone
Assessment
parameters
Summary of effects of tibolone
Vasomotor
symptoms
Significant and effective reduction in vasomotor symptoms
(hot flushes, vaginal dryness, sweating, and dryness of skin)
Urogenital
symptoms
Significantly lower incidence and recurrence of vaginal
bleeding/spotting
Significant improvement of lower vaginal tract symptoms
Improvement in vaginal cytology
Sexual health Improvement in sexual health and loss of libido
Increased sexual frequency, satisfaction and enjoyment
Significant reduction in SHBG
Increase in free testosterone levels
Mood Improvement in mood
Key Take Home Messages—
Comparison of Tibolone with
other Therapy Options
Assessment
parameters
Tibolone vs.
Estrogen+progesterone (E+P) Raloxifene
Bone Significantly greater increase in lumbar spine,
trochanter and total hip BMD with tibolone
Significantly greater
increase in lumbar
spine and total hip
BMD with tibolone
Endometrium No difference in the incidence of proliferation,
endometrial hyperplasia or cancer
More frequent amenorrhea with tibolone
-
Breast pain
and
Density
Significantly lower incidence of breast
pain/tenderness/mastalgia with tibolone
Greater increase in mammographic breast
density with E+P
Decrease in breast density score with tibolone
vs. increase with E+P
Decreased expression of
immunohistochemical markers with tibolone
Be Passionate and Exciting
Excitement is contagious- just like a Yawn
A Mediocre person tells.
A good persons explains
A superior person demonstrates
A great person inspires others
to see & makeup their mind for
themselves Harvey Mackey
Be
Clear
And
Direct
SURGICAL MENOPAUSE • Livial
• Miniasprin
• Esosteo
Recurrent Vag / UTI • Livial
• Rule out DM
• Neuro Dermatitis
• Local Oest. cream
Moderate to severe
Dyspareunia
• Livial
• Local estrogen
• Counseling of Couple
Answer Question Directly And clearly
If you are asked a question and you give a “POLITICIAN’S ANSWERS” – in other
words, if You Don’t answer the question – your credibility will decline,
Thank You
Hope Some Clarity is There !!
ADDRESS
35 , Defence Enclave, Opp. Preet Vihar
Petrol Pump, Metro pillar no. 88, Vikas
Marg , Delhi – 110092
CONTACT US
011-22414049, 42401339
WEBSITE :
www.lifecarecentre.in
www.drshardajain.com
www.lifecareivf.com
E-MAIL ID
Sharda.lifecare@gmail.com
Lifecarecentre21@gmail.com
info@lifecareivf.com
&

Más contenido relacionado

La actualidad más candente

Menopause management seminar
Menopause management seminarMenopause management seminar
Menopause management seminar
obsgynhsnz
 
HORMONE REPLACEMENT THERAPY 2
HORMONE REPLACEMENT THERAPY 2HORMONE REPLACEMENT THERAPY 2
HORMONE REPLACEMENT THERAPY 2
Karl Daniel, M.D.
 
Menopause Presentation
Menopause PresentationMenopause Presentation
Menopause Presentation
Megan Handley
 
Management of INFERTILITY in PCOD Difficulties & Solutions Made Easy , Dr....
Management of INFERTILITY in PCOD Difficulties & SolutionsMade Easy , Dr....Management of INFERTILITY in PCOD Difficulties & SolutionsMade Easy , Dr....
Management of INFERTILITY in PCOD Difficulties & Solutions Made Easy , Dr....
Lifecare Centre
 
Premature ovarian failure
Premature ovarian failurePremature ovarian failure
Premature ovarian failure
Shambhu N
 

La actualidad más candente (20)

Update on LETROZOLE Current Guidelines for Ovulation Induction Dr. Sharda Jain
Update on LETROZOLE Current Guidelines for Ovulation Induction Dr. Sharda Jain Update on LETROZOLE Current Guidelines for Ovulation Induction Dr. Sharda Jain
Update on LETROZOLE Current Guidelines for Ovulation Induction Dr. Sharda Jain
 
Step by Step Guide to Menopause Hormone Therapy by Dr. laxmi Shrikhande
Step by Step Guide to Menopause Hormone Therapy by Dr. laxmi ShrikhandeStep by Step Guide to Menopause Hormone Therapy by Dr. laxmi Shrikhande
Step by Step Guide to Menopause Hormone Therapy by Dr. laxmi Shrikhande
 
Updated hormone replacement therapy
Updated hormone replacement therapyUpdated hormone replacement therapy
Updated hormone replacement therapy
 
Menopausal Harmone Therapy & Indian Gynaecologists Dr Sharda Jain
Menopausal Harmone Therapy &  Indian Gynaecologists Dr Sharda Jain Menopausal Harmone Therapy &  Indian Gynaecologists Dr Sharda Jain
Menopausal Harmone Therapy & Indian Gynaecologists Dr Sharda Jain
 
Menopause
Menopause Menopause
Menopause
 
Management of diabetes during pregnancy
Management of diabetes during pregnancyManagement of diabetes during pregnancy
Management of diabetes during pregnancy
 
Menopause management seminar
Menopause management seminarMenopause management seminar
Menopause management seminar
 
PCOS - Ovulation Induction 1 - Dr Bharati Dhorepatil
PCOS - Ovulation Induction 1 - Dr Bharati DhorepatilPCOS - Ovulation Induction 1 - Dr Bharati Dhorepatil
PCOS - Ovulation Induction 1 - Dr Bharati Dhorepatil
 
Progesterone in gynecology
Progesterone in gynecologyProgesterone in gynecology
Progesterone in gynecology
 
HORMONE REPLACEMENT THERAPY 2
HORMONE REPLACEMENT THERAPY 2HORMONE REPLACEMENT THERAPY 2
HORMONE REPLACEMENT THERAPY 2
 
DIENOGEST BY DR SHASHWAT JANI
DIENOGEST BY DR SHASHWAT JANIDIENOGEST BY DR SHASHWAT JANI
DIENOGEST BY DR SHASHWAT JANI
 
Menopause Presentation
Menopause PresentationMenopause Presentation
Menopause Presentation
 
Endometriosis and Infertility
Endometriosis and InfertilityEndometriosis and Infertility
Endometriosis and Infertility
 
Menopause
MenopauseMenopause
Menopause
 
Menopause: Diagnosis and Management. Prof ABOUBAKR ELNASHAR
Menopause: Diagnosis and Management. Prof ABOUBAKR ELNASHAR Menopause: Diagnosis and Management. Prof ABOUBAKR ELNASHAR
Menopause: Diagnosis and Management. Prof ABOUBAKR ELNASHAR
 
The menopause cure
The menopause cureThe menopause cure
The menopause cure
 
Ulipristal acetate in treatment of fibroids
Ulipristal acetate in treatment of fibroidsUlipristal acetate in treatment of fibroids
Ulipristal acetate in treatment of fibroids
 
Hypothyroidism During pregnancy
Hypothyroidism During pregnancyHypothyroidism During pregnancy
Hypothyroidism During pregnancy
 
Management of INFERTILITY in PCOD Difficulties & Solutions Made Easy , Dr....
Management of INFERTILITY in PCOD Difficulties & SolutionsMade Easy , Dr....Management of INFERTILITY in PCOD Difficulties & SolutionsMade Easy , Dr....
Management of INFERTILITY in PCOD Difficulties & Solutions Made Easy , Dr....
 
Premature ovarian failure
Premature ovarian failurePremature ovarian failure
Premature ovarian failure
 

Similar a Hormone replacement therapy dr. sharda jain

Medical management of dub – new modalities dr. jyoti bhaskar lecture 4
Medical management of dub – new modalities dr. jyoti bhaskar lecture   4Medical management of dub – new modalities dr. jyoti bhaskar lecture   4
Medical management of dub – new modalities dr. jyoti bhaskar lecture 4
Lifecare Centre
 
Medical management of dub – new modalities
Medical management of dub – new modalitiesMedical management of dub – new modalities
Medical management of dub – new modalities
Lifecare Centre
 
Healthrisks co cs
Healthrisks co csHealthrisks co cs
Healthrisks co cs
Naz Kasim
 
pdfslide.net_adam-syndrome-androgen-deficiency-in-the-aging-man-andropause-56...
pdfslide.net_adam-syndrome-androgen-deficiency-in-the-aging-man-andropause-56...pdfslide.net_adam-syndrome-androgen-deficiency-in-the-aging-man-andropause-56...
pdfslide.net_adam-syndrome-androgen-deficiency-in-the-aging-man-andropause-56...
GlobalProvidence
 
Is hrt a replacement medication
Is hrt a replacement medicationIs hrt a replacement medication
Is hrt a replacement medication
falcaoebarros
 
Endocrine Therapy In Advanced Breast Cancer
Endocrine Therapy In Advanced Breast CancerEndocrine Therapy In Advanced Breast Cancer
Endocrine Therapy In Advanced Breast Cancer
guest8887a7
 
BALKAN MCO 2011 - T. Cufer - Hormonal therapy options/management in metastati...
BALKAN MCO 2011 - T. Cufer - Hormonal therapy options/management in metastati...BALKAN MCO 2011 - T. Cufer - Hormonal therapy options/management in metastati...
BALKAN MCO 2011 - T. Cufer - Hormonal therapy options/management in metastati...
European School of Oncology
 

Similar a Hormone replacement therapy dr. sharda jain (20)

Alternative Menopausal Hormone Therapies.pdf
Alternative Menopausal Hormone Therapies.pdfAlternative Menopausal Hormone Therapies.pdf
Alternative Menopausal Hormone Therapies.pdf
 
Endometriosis and menopausal hormone therapy
Endometriosis and menopausal hormone therapyEndometriosis and menopausal hormone therapy
Endometriosis and menopausal hormone therapy
 
Tissue specific estrogen complex
Tissue specific estrogen complexTissue specific estrogen complex
Tissue specific estrogen complex
 
Alternative hormone treatments for postmenopausal symptoms
Alternative hormone treatments for postmenopausal symptomsAlternative hormone treatments for postmenopausal symptoms
Alternative hormone treatments for postmenopausal symptoms
 
Andropause & Sarcopenia , Prabhakar Shetty
Andropause & Sarcopenia , Prabhakar ShettyAndropause & Sarcopenia , Prabhakar Shetty
Andropause & Sarcopenia , Prabhakar Shetty
 
Medical management of dub – new modalities dr. jyoti bhaskar lecture 4
Medical management of dub – new modalities dr. jyoti bhaskar lecture   4Medical management of dub – new modalities dr. jyoti bhaskar lecture   4
Medical management of dub – new modalities dr. jyoti bhaskar lecture 4
 
Tribestan 2015
Tribestan 2015Tribestan 2015
Tribestan 2015
 
Medical management of dub – new modalities
Medical management of dub – new modalitiesMedical management of dub – new modalities
Medical management of dub – new modalities
 
Florenz imhof 2006
Florenz imhof 2006Florenz imhof 2006
Florenz imhof 2006
 
Healthrisks co cs
Healthrisks co csHealthrisks co cs
Healthrisks co cs
 
D de Jong, Prostate cancer brachytherapy
D de Jong, Prostate cancer brachytherapyD de Jong, Prostate cancer brachytherapy
D de Jong, Prostate cancer brachytherapy
 
Hormone Replacement Therapy
Hormone Replacement TherapyHormone Replacement Therapy
Hormone Replacement Therapy
 
pdfslide.net_adam-syndrome-androgen-deficiency-in-the-aging-man-andropause-56...
pdfslide.net_adam-syndrome-androgen-deficiency-in-the-aging-man-andropause-56...pdfslide.net_adam-syndrome-androgen-deficiency-in-the-aging-man-andropause-56...
pdfslide.net_adam-syndrome-androgen-deficiency-in-the-aging-man-andropause-56...
 
Is hrt a replacement medication
Is hrt a replacement medicationIs hrt a replacement medication
Is hrt a replacement medication
 
Endocrine Therapy In Advanced Breast Cancer
Endocrine Therapy In Advanced Breast CancerEndocrine Therapy In Advanced Breast Cancer
Endocrine Therapy In Advanced Breast Cancer
 
Update (2021) Oral Contraceptive Pill : Dr. Jyoti Agarwal Dr Sharda Jain
Update (2021) Oral Contraceptive Pill : Dr. Jyoti Agarwal Dr Sharda Jain Update (2021) Oral Contraceptive Pill : Dr. Jyoti Agarwal Dr Sharda Jain
Update (2021) Oral Contraceptive Pill : Dr. Jyoti Agarwal Dr Sharda Jain
 
Cytokines IN FIBROMYALGIA SYNDROME
Cytokines IN  FIBROMYALGIA SYNDROMECytokines IN  FIBROMYALGIA SYNDROME
Cytokines IN FIBROMYALGIA SYNDROME
 
BALKAN MCO 2011 - T. Cufer - Hormonal therapy options/management in metastati...
BALKAN MCO 2011 - T. Cufer - Hormonal therapy options/management in metastati...BALKAN MCO 2011 - T. Cufer - Hormonal therapy options/management in metastati...
BALKAN MCO 2011 - T. Cufer - Hormonal therapy options/management in metastati...
 
Recent advances in hormonal contraception malini
Recent advances in hormonal contraception maliniRecent advances in hormonal contraception malini
Recent advances in hormonal contraception malini
 
Isoflavones
IsoflavonesIsoflavones
Isoflavones
 

Más de Lifecare Centre

Más de Lifecare Centre (20)

Anemia Free India Gynaecologist to focuss on *12gm Haemoglobin at Delivery I...
Anemia Free India Gynaecologist  to focuss on *12gm Haemoglobin at Delivery I...Anemia Free India Gynaecologist  to focuss on *12gm Haemoglobin at Delivery I...
Anemia Free India Gynaecologist to focuss on *12gm Haemoglobin at Delivery I...
 
7 steps How to prevent Thalassemia : Dr Sharda Jain & Vandana Gupta
7 steps How to prevent Thalassemia : Dr Sharda Jain & Vandana Gupta7 steps How to prevent Thalassemia : Dr Sharda Jain & Vandana Gupta
7 steps How to prevent Thalassemia : Dr Sharda Jain & Vandana Gupta
 
Liver Dialogue for Gynaecologists : Dr Sharda Jain
Liver Dialogue for Gynaecologists : Dr Sharda JainLiver Dialogue for Gynaecologists : Dr Sharda Jain
Liver Dialogue for Gynaecologists : Dr Sharda Jain
 
National Tuberculosis elimination programme (NIKSHAY) Big Challenge to GOI : ...
National Tuberculosis elimination programme (NIKSHAY)Big Challenge to GOI : ...National Tuberculosis elimination programme (NIKSHAY)Big Challenge to GOI : ...
National Tuberculosis elimination programme (NIKSHAY) Big Challenge to GOI : ...
 
Innovations & Breakthrough in IVF PART 3
Innovations & Breakthrough in IVF PART 3Innovations & Breakthrough in IVF PART 3
Innovations & Breakthrough in IVF PART 3
 
Strategies for Improving Success Rates in ART PART
Strategies for Improving Success Rates in ART PARTStrategies for Improving Success Rates in ART PART
Strategies for Improving Success Rates in ART PART
 
20 Simple ways for the Indian public to save water on World Water Day : Dr Sh...
20 Simple ways for the Indian public to save water on World Water Day : Dr Sh...20 Simple ways for the Indian public to save water on World Water Day : Dr Sh...
20 Simple ways for the Indian public to save water on World Water Day : Dr Sh...
 
Vaccination during Pregnancy & its Importance : Dr Sharda Jain
Vaccination during Pregnancy & its Importance : Dr Sharda JainVaccination during Pregnancy & its Importance : Dr Sharda Jain
Vaccination during Pregnancy & its Importance : Dr Sharda Jain
 
How to optimize success rates in ART? : Dr Sharda Jain
How to optimize success rates in ART? : Dr Sharda JainHow to optimize success rates in ART? : Dr Sharda Jain
How to optimize success rates in ART? : Dr Sharda Jain
 
SOCIALEGG FREEZING : Dr Poorva Bhargav and Dr Sharda Jain
SOCIALEGG FREEZING : Dr Poorva Bhargav  and Dr Sharda JainSOCIALEGG FREEZING : Dr Poorva Bhargav  and Dr Sharda Jain
SOCIALEGG FREEZING : Dr Poorva Bhargav and Dr Sharda Jain
 
White Coat Hypertension During Pregnancy : Dr Sharda Jain
White Coat Hypertension During Pregnancy : Dr Sharda JainWhite Coat Hypertension During Pregnancy : Dr Sharda Jain
White Coat Hypertension During Pregnancy : Dr Sharda Jain
 
White Coat hypertension Why it is Important? : Dr Sharda Jain
White Coat hypertension Why it is  Important? : Dr Sharda JainWhite Coat hypertension Why it is  Important? : Dr Sharda Jain
White Coat hypertension Why it is Important? : Dr Sharda Jain
 
Understanding Blood Pressure Reading During Pregnancy : Dr Sharda Jain
Understanding Blood Pressure Reading During Pregnancy : Dr Sharda JainUnderstanding Blood Pressure Reading During Pregnancy : Dr Sharda Jain
Understanding Blood Pressure Reading During Pregnancy : Dr Sharda Jain
 
Know Your Blood Pressure Understanding Blood Pressure Reading : Dr Sharda Jain
Know Your Blood Pressure Understanding Blood Pressure Reading : Dr Sharda JainKnow Your Blood Pressure Understanding Blood Pressure Reading : Dr Sharda Jain
Know Your Blood Pressure Understanding Blood Pressure Reading : Dr Sharda Jain
 
Still Birth:An Update : Dr Sharda Jain
Still Birth:An Update : Dr Sharda JainStill Birth:An Update : Dr Sharda Jain
Still Birth:An Update : Dr Sharda Jain
 
IRON DEFICIENCY ANEMIA OVERVIEW WITH FOCUS ON PARENTRAL IRON THERAPY : Dr ...
IRON DEFICIENCY ANEMIA  OVERVIEW  WITH FOCUS ON PARENTRAL IRON THERAPY  : Dr ...IRON DEFICIENCY ANEMIA  OVERVIEW  WITH FOCUS ON PARENTRAL IRON THERAPY  : Dr ...
IRON DEFICIENCY ANEMIA OVERVIEW WITH FOCUS ON PARENTRAL IRON THERAPY : Dr ...
 
Iron Deficiency Anemia in Pregnancy Role of IV Ferric Carboxymaltose and its ...
Iron Deficiency Anemia in PregnancyRole of IV Ferric Carboxymaltose andits ...Iron Deficiency Anemia in PregnancyRole of IV Ferric Carboxymaltose andits ...
Iron Deficiency Anemia in Pregnancy Role of IV Ferric Carboxymaltose and its ...
 
CHECK LIST FOR ART SPECIALIST BEFORE IVF-ICSI FOR PATIENTS SEEKING IVF -ICSI ...
CHECK LIST FOR ART SPECIALIST BEFORE IVF-ICSI FOR PATIENTS SEEKING IVF -ICSI ...CHECK LIST FOR ART SPECIALIST BEFORE IVF-ICSI FOR PATIENTS SEEKING IVF -ICSI ...
CHECK LIST FOR ART SPECIALIST BEFORE IVF-ICSI FOR PATIENTS SEEKING IVF -ICSI ...
 
CMV UPDATE Few solid facts about cytomegalovirus (CMV) Infection & New devel...
CMV UPDATE Few solid facts  about cytomegalovirus (CMV) Infection & New devel...CMV UPDATE Few solid facts  about cytomegalovirus (CMV) Infection & New devel...
CMV UPDATE Few solid facts about cytomegalovirus (CMV) Infection & New devel...
 
Addressing the challenge of lack of Sleep in INDIA
Addressing the challenge of lack of Sleep in INDIA Addressing the challenge of lack of Sleep in INDIA
Addressing the challenge of lack of Sleep in INDIA
 

Último

Cara Menggugurkan Kandungan Dengan Cepat Selesai Dalam 24 Jam Secara Alami Bu...
Cara Menggugurkan Kandungan Dengan Cepat Selesai Dalam 24 Jam Secara Alami Bu...Cara Menggugurkan Kandungan Dengan Cepat Selesai Dalam 24 Jam Secara Alami Bu...
Cara Menggugurkan Kandungan Dengan Cepat Selesai Dalam 24 Jam Secara Alami Bu...
Cara Menggugurkan Kandungan 087776558899
 
Dehradun Call Girls Service {8854095900} ❤️VVIP ROCKY Call Girl in Dehradun U...
Dehradun Call Girls Service {8854095900} ❤️VVIP ROCKY Call Girl in Dehradun U...Dehradun Call Girls Service {8854095900} ❤️VVIP ROCKY Call Girl in Dehradun U...
Dehradun Call Girls Service {8854095900} ❤️VVIP ROCKY Call Girl in Dehradun U...
Sheetaleventcompany
 

Último (20)

Cardiac Output, Venous Return, and Their Regulation
Cardiac Output, Venous Return, and Their RegulationCardiac Output, Venous Return, and Their Regulation
Cardiac Output, Venous Return, and Their Regulation
 
💚Reliable Call Girls Chandigarh 💯Niamh 📲🔝8868886958🔝Call Girl In Chandigarh N...
💚Reliable Call Girls Chandigarh 💯Niamh 📲🔝8868886958🔝Call Girl In Chandigarh N...💚Reliable Call Girls Chandigarh 💯Niamh 📲🔝8868886958🔝Call Girl In Chandigarh N...
💚Reliable Call Girls Chandigarh 💯Niamh 📲🔝8868886958🔝Call Girl In Chandigarh N...
 
(RIYA)🎄Airhostess Call Girl Jaipur Call Now 8445551418 Premium Collection Of ...
(RIYA)🎄Airhostess Call Girl Jaipur Call Now 8445551418 Premium Collection Of ...(RIYA)🎄Airhostess Call Girl Jaipur Call Now 8445551418 Premium Collection Of ...
(RIYA)🎄Airhostess Call Girl Jaipur Call Now 8445551418 Premium Collection Of ...
 
Independent Bangalore Call Girls (Adult Only) 💯Call Us 🔝 7304373326 🔝 💃 Escor...
Independent Bangalore Call Girls (Adult Only) 💯Call Us 🔝 7304373326 🔝 💃 Escor...Independent Bangalore Call Girls (Adult Only) 💯Call Us 🔝 7304373326 🔝 💃 Escor...
Independent Bangalore Call Girls (Adult Only) 💯Call Us 🔝 7304373326 🔝 💃 Escor...
 
Cara Menggugurkan Kandungan Dengan Cepat Selesai Dalam 24 Jam Secara Alami Bu...
Cara Menggugurkan Kandungan Dengan Cepat Selesai Dalam 24 Jam Secara Alami Bu...Cara Menggugurkan Kandungan Dengan Cepat Selesai Dalam 24 Jam Secara Alami Bu...
Cara Menggugurkan Kandungan Dengan Cepat Selesai Dalam 24 Jam Secara Alami Bu...
 
Cheap Rate Call Girls Bangalore {9179660964} ❤️VVIP BEBO Call Girls in Bangal...
Cheap Rate Call Girls Bangalore {9179660964} ❤️VVIP BEBO Call Girls in Bangal...Cheap Rate Call Girls Bangalore {9179660964} ❤️VVIP BEBO Call Girls in Bangal...
Cheap Rate Call Girls Bangalore {9179660964} ❤️VVIP BEBO Call Girls in Bangal...
 
Circulatory Shock, types and stages, compensatory mechanisms
Circulatory Shock, types and stages, compensatory mechanismsCirculatory Shock, types and stages, compensatory mechanisms
Circulatory Shock, types and stages, compensatory mechanisms
 
Kolkata Call Girls Naktala 💯Call Us 🔝 8005736733 🔝 💃 Top Class Call Girl Se...
Kolkata Call Girls Naktala  💯Call Us 🔝 8005736733 🔝 💃  Top Class Call Girl Se...Kolkata Call Girls Naktala  💯Call Us 🔝 8005736733 🔝 💃  Top Class Call Girl Se...
Kolkata Call Girls Naktala 💯Call Us 🔝 8005736733 🔝 💃 Top Class Call Girl Se...
 
Call Girls Kathua Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Kathua Just Call 8250077686 Top Class Call Girl Service AvailableCall Girls Kathua Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Kathua Just Call 8250077686 Top Class Call Girl Service Available
 
Bhawanipatna Call Girls 📞9332606886 Call Girls in Bhawanipatna Escorts servic...
Bhawanipatna Call Girls 📞9332606886 Call Girls in Bhawanipatna Escorts servic...Bhawanipatna Call Girls 📞9332606886 Call Girls in Bhawanipatna Escorts servic...
Bhawanipatna Call Girls 📞9332606886 Call Girls in Bhawanipatna Escorts servic...
 
Call Girls Rishikesh Just Call 9667172968 Top Class Call Girl Service Available
Call Girls Rishikesh Just Call 9667172968 Top Class Call Girl Service AvailableCall Girls Rishikesh Just Call 9667172968 Top Class Call Girl Service Available
Call Girls Rishikesh Just Call 9667172968 Top Class Call Girl Service Available
 
Call Girls Shahdol Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Shahdol Just Call 8250077686 Top Class Call Girl Service AvailableCall Girls Shahdol Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Shahdol Just Call 8250077686 Top Class Call Girl Service Available
 
❤️Chandigarh Escorts Service☎️9814379184☎️ Call Girl service in Chandigarh☎️ ...
❤️Chandigarh Escorts Service☎️9814379184☎️ Call Girl service in Chandigarh☎️ ...❤️Chandigarh Escorts Service☎️9814379184☎️ Call Girl service in Chandigarh☎️ ...
❤️Chandigarh Escorts Service☎️9814379184☎️ Call Girl service in Chandigarh☎️ ...
 
Low Cost Call Girls Bangalore {9179660964} ❤️VVIP NISHA Call Girls in Bangalo...
Low Cost Call Girls Bangalore {9179660964} ❤️VVIP NISHA Call Girls in Bangalo...Low Cost Call Girls Bangalore {9179660964} ❤️VVIP NISHA Call Girls in Bangalo...
Low Cost Call Girls Bangalore {9179660964} ❤️VVIP NISHA Call Girls in Bangalo...
 
ANATOMY AND PHYSIOLOGY OF RESPIRATORY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF RESPIRATORY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF RESPIRATORY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF RESPIRATORY SYSTEM.pptx
 
Dehradun Call Girls Service {8854095900} ❤️VVIP ROCKY Call Girl in Dehradun U...
Dehradun Call Girls Service {8854095900} ❤️VVIP ROCKY Call Girl in Dehradun U...Dehradun Call Girls Service {8854095900} ❤️VVIP ROCKY Call Girl in Dehradun U...
Dehradun Call Girls Service {8854095900} ❤️VVIP ROCKY Call Girl in Dehradun U...
 
Gastric Cancer: Сlinical Implementation of Artificial Intelligence, Synergeti...
Gastric Cancer: Сlinical Implementation of Artificial Intelligence, Synergeti...Gastric Cancer: Сlinical Implementation of Artificial Intelligence, Synergeti...
Gastric Cancer: Сlinical Implementation of Artificial Intelligence, Synergeti...
 
Race Course Road } Book Call Girls in Bangalore | Whatsapp No 6378878445 VIP ...
Race Course Road } Book Call Girls in Bangalore | Whatsapp No 6378878445 VIP ...Race Course Road } Book Call Girls in Bangalore | Whatsapp No 6378878445 VIP ...
Race Course Road } Book Call Girls in Bangalore | Whatsapp No 6378878445 VIP ...
 
Call Girl In Chandigarh 📞9809698092📞 Just📲 Call Inaaya Chandigarh Call Girls ...
Call Girl In Chandigarh 📞9809698092📞 Just📲 Call Inaaya Chandigarh Call Girls ...Call Girl In Chandigarh 📞9809698092📞 Just📲 Call Inaaya Chandigarh Call Girls ...
Call Girl In Chandigarh 📞9809698092📞 Just📲 Call Inaaya Chandigarh Call Girls ...
 
Call Girls in Lucknow Just Call 👉👉 8875999948 Top Class Call Girl Service Ava...
Call Girls in Lucknow Just Call 👉👉 8875999948 Top Class Call Girl Service Ava...Call Girls in Lucknow Just Call 👉👉 8875999948 Top Class Call Girl Service Ava...
Call Girls in Lucknow Just Call 👉👉 8875999948 Top Class Call Girl Service Ava...
 

Hormone replacement therapy dr. sharda jain

  • 2. Dr. Sharda Jain MD(PGIMER), MNAMS, FICOG FIMSA, DHM,QM & AHO Director :- Sec General : Delhi Gynae Forum
  • 4. We all are Confused
  • 5. In Last 15 years - this is my 15th presentation
  • 6. PRESENTATION is an ART , Not a science . Which means It's Never perfect and can always improve.
  • 7.
  • 8.
  • 9.
  • 11. Put your self in a customer’s place Most unhappy customer are greatest source of learning
  • 12. Menopause  Menopause marks the end of reproductive capacity of women and results from the permanent cessation of ovarian function  The median age for the onset of menopause: 51.4 years  Indian Context: 40.32–48.84 years  By 2015, about 130 million Indian women are expected to live beyond menopause Menopausal transition Xu J, et al. J Am Board Fam Pract. 2005;18:374–382. Umland ME. J Manag Care Pharm. 2008;14(3)(suppl S):S14–S19. Sharma S, et al. JK Sci. 2007;9(1):13–17. Aarti K. J Obst Gynecol India. 2011;323–326.
  • 13. Menopause Long Term Effects Symptoms Vasomotor Urogenital Mood /Cognitive Osteoporosis Poor Bowel / Bladder Vision H. Dis. Skin M.Tone
  • 14. Complaints % western women West India North India Irritability 92 48 36 Lethargy 88 45 - Depression 78 43 10 Flushes and night sweats 75 38 22 Headaches 64 27 15 Forgetfulness 61 60 65 Weight gain insomnia 51 60 70 How Common Are the various menopause symptoms
  • 15. Relative frequency of climacteric Symptoms in India Symptoms India Incidence Anklesaria 1995 Krishna 1995 Hot Flashes 30% 33% Urinary Complaints 74% 35% Vaginal Symptoms 56% 50% Joint/ Muscle pain 20% 25% Psychological 36% 20%
  • 18. Principles •Time – Shortest possible •Dose – Smallest possible •Counseling – All short & long term risks is mandatory of HT
  • 19.
  • 20.
  • 21.
  • 23. Structure and Mechanism of Action  Tibolone is a selective tissue oestrogenic activity regulator.  Tibolone substitutes for the loss of oestrogen production in postmenopausal women, and alleviates menopausal symptoms.  Tibolone prevents bone loss following menopause or ovariectomy 1960/70 Steckelbroeck S, et al. Mol Pharmacol.2004;66: 1702–1711. Tibolone summary of product characteristics. Available at: www.medicines.org.uk.
  • 24. Specific binding affinities of tibolone and its primary metabolites
  • 25. Tissue-Specific Effects of Tibolone’s Metabolites Modelska K, et al. J Clin Endocrinol Metab. 2002;87(1):16–23. Palacios S. Eur Heart J Supplements. 2001; 3 (Suppl M): M12–M16. +: Stimulatory effect;-: Suppressive effect; ?: Unknown effect
  • 26. Tissue-Specific Effects of Treatment Modalities for Menopause: The Tibolone Edge Tibolone Estrogen Estrogen+ progesterone Raloxifene (SERM) Bone (BMD) + + + + Climacteric symptoms + + + - Vagina + - - + Mood & libido ++ =/+ = = Endometrium = - - = Breast pain & density = - - = Breast cancer = - - =/+ Venous thromboembolism = - - - Myocardial infarction/stroke = - - = STEAR: Selective, tissue estrogenic activity regulator ; SERMs: Selective estrogen receptor modulator. +: Positive (beneficial effect); =: Neutral effect; -: Negative (detrimental) effect Kloosterboer HJ. J Steroid Biochem Mol Biol.2003;83: 157–165. The clinical profile of tibolone has advantages over other treatment modalities
  • 27. Effect of Tibolone on Vasomotor and Urogenital Symptoms of Menopause
  • 28. Summary of Comparison of Tibolone with Combine HT Assessment parameters Tibolone vs. estrogen+progesterone HT Vasomotor symptoms Comparable and significant reduction inhot flashes, sweating and vaginal dryness. Better improvement in dryness of skin with tibolone
  • 29. Hot flushes: tibolone versus CHT (Comparable) Baracat et al.Climacteric 2002 Control of vasomotor symptoms *Significantly different from baseline; CEE, conjugated equine estrogens; MPA, medroxyprogesterone acetate Meanvalue 14 12 10 8 6 4 2 0 Baseline 3 6 9 13 * * * * * * * * Tibolone (n = 40) CEE/MPA (n = 45) Hot flushes Treatment cycle
  • 30. Clinical Evidence 1: Tolerability Trial comparing Livial vs E2 / NETA Objective: To compare the efficacy and safety of tibolone vs. low-dose continuous combined estradiol plus norethisterone acetate (E2/NETA) in healthy symptomatic postmenopausal women (age: 45–65 years) (n=572). Study Endpoints: Prevalence of vaginal bleeding, hot flushes and adverse events. Study Results  Comparable reductions in vasomotor symptoms and vaginal atrophy in both the groups.  Significantly lower incidence of vaginal bleeding and breast pain/tenderness in the tibolone group. Conclusion: Tibolone produced effective and comparable reduction in menopausal symptoms, and was associated with a lower incidence of vaginal bleeding and breast pain/tenderness vs. E2/NETA. Hammar ML, et al. BJOG. 2007;114(12):1522–1529.
  • 31. Tibolone V/S HT Urogenital symptoms Significantly lower incidence and recurrence of vaginal bleeding/spotting Significant improvement of lower vaginal tract symptoms Improvement in vaginal cytology
  • 32. Clinical Evidence 2: Long-Term Effects of Tibolone on Urogenital Symptoms Objective: To evaluate the effects of six years of tibolone therapy on the genital tract in postmenopausal women (n=113). Study Endpoints: Assessment of urogenital symptoms, vaginal epithelial activity and calculation of vaginal karyopyknotic index and maturation index. Study Results  Significant improvement in the lower genital tract symptoms in comparison to control.  Significant increase in the karyopyknotic index and maturation index in the tibolone group.  Improvement in vaginal symptomatology with minimal endometrial stimulation. Conclusion: Tibolone was effective at maintaining an inactive endometrium while providing oestrogenisation of the lower genital tract. Morris EP, et al. Br J Obstet Gynaecol. 1999;106(9):954–959.
  • 33. Assessment parameters Tibolone vs. Estrogen+progesterone (E+P) Raloxifene Bone Significantly greater increase in lumbar spine, trochanter and total hip BMD with tibolone Significantly greater increase in lumbar spine and total hip BMD with tibolone Tibolone V/S HT (E + P) & Raloxifene BONE
  • 34. Clinical Evidence 1: Study of Tibolone V/s raloxifene Effects on osteoPenia (STEP) Objective: To compare the efficacy of tibolone vs. raloxifene on BMD of the lumbar spine and hip in osteopenic postmenopausal women (n=308). Endpoints: Measurement of BMD, serum osteocalcin and serum type I collagen C-telopeptides Study Results  Larger increase in lumbar spine BMD after 1- and 2- years and total hip BMD after 2 years of therapy with tibolone vs. raloxifene.  Comparable reductions in serum osteocalcin and serum type I collagen C-telopeptides . Conclusion: Tibolone prevented postmenopausal bone loss in older women and resulted in a larger increase of BMD both at the lumbar spine and hip than raloxifene Delmas PD, et al. Osteoporos Int. 2008;19(8):1153– 1160. Tibolone vs. raloxifene p<0.01 for lumbar BMD (1 y) p<0.001 for lumbar BMD (2 y) p<0.05 for total hip BMD (2 y)
  • 35. Clinical Evidence 2: Long-term Intervention on Fractures with Tibolone (LIFT) Objective: To assess the efficacy of tibolone in preventing bone loss and its effects on fractures, breast cancer and cardiovascular disease. Endpoints: Assessment of vertebral fractures and rates of cardiovascular disease and breast cancer. Study Results  Increase in BMD of the spine and femoral neck in the tibolone group.  Decreased risk of vertebral and non-vertebral fractures with tibolone.  Decreased risk of invasive breast cancer and colon cancer with tibolone therapy.  Increased risk of stroke, but no difference in the risk of coronary heart disease or venous thromboembolism with tibolone vs. placebo. Conclusion: Tibolone reduced the risk of fracture and breast cancer and possibly colon cancer in older women with osteoporosis. B Cummings SR, et al. N Engl J Med. 2008;359(7):697–708.
  • 36. Summary of Effects of Tibolone V/S HRT SEXUAL HEALTH Improvement in sexual health and loss of libido Increased sexual frequency, satisfaction and enjoyment Significant reduction in SHBG Increase in free testosterone levels MOOD Improvement in mood
  • 37.
  • 38. Clinical Evidence 2: Efficacy of Tibolone vs. Conventional HRT on Sexual Function Objective: To compare the effects of TIBOLONE VS. CONVENTIONAL HORMONE REPLACEMENT THERAPY on climacteric symptoms and sexual function in postmenopausal women (n=140). Endpoints: Evaluation of the GCS questionnaire and Rosen's FSFI. Measurement of SHBG, FEI and FTI. Follow-up period: 6 months. Study Results  Comparable improvement in climacteric symptoms.  Greater improvement in the sexual subscore of GCS in the tibolone group.  Greater improvement in the desire, arousal and orgasm sexual domains of the FSFI in the tibolone group  Greater and significant reduction in SHBG and increase in FEI and FTI in the tibolone group. Conclusion: Tibolone was found to be an effective alternative to conventional HRT in the treatment of climacteric symptoms and sexual dysfunction in postmenopausal women. Ziaei S, et al. Climacteric. 2010;13(2):147–156. p<0.001 for tibolone vs. CEE/MPA and control
  • 39. ENDOMETRIUM NO DIFFERENCE IN THE INCIDENCE OF PROLIFERATION, ENDOMETRIAL HYPERPLASIA OR CANCER MORE FREQUENT AMENORRHEA WITH TIBOLONE Summary of Comparison of Tibolone with HRT ( E2/ NETA)
  • 40. Clinical Evidence 1: Tibolone v/S HRT Histology on the Endometrium and Breast Endpoints Study (THEBES) Objective: To compare the endometrial safety of tibolone vs. CEE/MPA in healthy postmenopausal women (n=3240) Endpoints: Evaluation of the incidence of abnormal endometrial histology (hyperplasia or carcinoma) and hyperplasia and carcinoma after 1 and 2 years of treatment. Study Results  No endometrial hyperplasia in the tibolone group.  More frequent amenorrhea was reported with tibolone 1.25 mg (78.7%) and 2.5 mg (71.4%) than CEE/MPA (44.9%).  Low incidence of breast pain in the tibolone group. Conclusion: Tibolone did not induce endometrial hyperplasia or carcinoma in post-menopausal women, and was associated with a better vaginal bleeding profile than CEE/MPA. Archer DF, et al. J Clin Endocrinol Metab. 2007;92(3):911–918.
  • 41. Key Take Home Messages— Tibolone Breast Cancer Breast Cancer Effective in symptomatic breast cancer patients, with improvement in quality of life*
  • 42. Tibolone & Breast pain and density Breast pain & density Lower incidence/decrease in breast pain/tenderness/mastalgia No increase in mammographic density of breast Decrease in breast density scores Decreased expression of immunohistochemical markers
  • 43. Tibolone Does Not Increase the Mammographic Breast Density Lundström E, et al. Am J Obstet Gynecol. 2002;186(4):717–722.
  • 44. Clinical Evidence: Tibolone vs. 17β-Estradiol in SURGICAL MENOPAUSE Objective: To compare the effectiveness of tibolone and 17β-estradiol on climacteric symptoms in surgically menopausal women (n=40) Endpoints: Assessment of climacteric symptoms with Greene Climacteric Scale at baseline, during washout and after the treatments. Study Results  Significant improvement from baseline in all the subscale scores in both study groups.  Improvement in psychological, somatic and sexual subscales was significantly superior in the tibolone group.  Comparable relief of vasomotor symptoms in both groups Conclusion: Tibolone may improve mood, libido and somatic symptoms in surgically menopausal women to a greater extent than estrogen therapy alone. Somunkiran A, et al. Maturitas. 2007;56(1):61–68.
  • 45. Clinical Evidence: Effect of Tibolone on Health-Related Quality of Life Objective: To assess the improvements in HRQOL in menopausal women using tibolone (n=100). Endpoints: Assessment of change in HRQOL after 3 and 12 months of treatment. Study Results  Significant improvement in HRQOL after 3 and 12 months of treatment with tibolone.  Maximal improvement was observed in the somatovegetative subscale. Conclusion: Tibolone was found to be effective in improving the overall HRQOL of menopausal women. Somatovegetative symptoms showed most improvement. Bhattacharya SM. Int J Gynaecol Obstet. 2007;99(1):43–45. Somatoveget ative complaints Psycholo gical complain ts Urogenita l complaint s Baseline 9.9 12.2 7 After 3 months 5.3 5 2.9 After 12 months 3.8 4.4 2.4
  • 47. Huang K-E, et al. Climacteric. 2010;13:317–327. Key Take Home Messages— Summary of Effects of Tibolone Assessment parameters Summary of effects of tibolone Vasomotor symptoms Significant and effective reduction in vasomotor symptoms (hot flushes, vaginal dryness, sweating, and dryness of skin) Urogenital symptoms Significantly lower incidence and recurrence of vaginal bleeding/spotting Significant improvement of lower vaginal tract symptoms Improvement in vaginal cytology Sexual health Improvement in sexual health and loss of libido Increased sexual frequency, satisfaction and enjoyment Significant reduction in SHBG Increase in free testosterone levels Mood Improvement in mood
  • 48. Key Take Home Messages— Comparison of Tibolone with other Therapy Options Assessment parameters Tibolone vs. Estrogen+progesterone (E+P) Raloxifene Bone Significantly greater increase in lumbar spine, trochanter and total hip BMD with tibolone Significantly greater increase in lumbar spine and total hip BMD with tibolone Endometrium No difference in the incidence of proliferation, endometrial hyperplasia or cancer More frequent amenorrhea with tibolone - Breast pain and Density Significantly lower incidence of breast pain/tenderness/mastalgia with tibolone Greater increase in mammographic breast density with E+P Decrease in breast density score with tibolone vs. increase with E+P Decreased expression of immunohistochemical markers with tibolone
  • 49. Be Passionate and Exciting Excitement is contagious- just like a Yawn
  • 50. A Mediocre person tells. A good persons explains A superior person demonstrates A great person inspires others to see & makeup their mind for themselves Harvey Mackey
  • 52. SURGICAL MENOPAUSE • Livial • Miniasprin • Esosteo Recurrent Vag / UTI • Livial • Rule out DM • Neuro Dermatitis • Local Oest. cream Moderate to severe Dyspareunia • Livial • Local estrogen • Counseling of Couple
  • 53.
  • 54. Answer Question Directly And clearly If you are asked a question and you give a “POLITICIAN’S ANSWERS” – in other words, if You Don’t answer the question – your credibility will decline,
  • 55.
  • 56.
  • 58. Hope Some Clarity is There !!
  • 59. ADDRESS 35 , Defence Enclave, Opp. Preet Vihar Petrol Pump, Metro pillar no. 88, Vikas Marg , Delhi – 110092 CONTACT US 011-22414049, 42401339 WEBSITE : www.lifecarecentre.in www.drshardajain.com www.lifecareivf.com E-MAIL ID Sharda.lifecare@gmail.com Lifecarecentre21@gmail.com info@lifecareivf.com &

Notas del editor

  1. Tibolone ([7,17]-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one) is a hormone replacement therapeutic used in the treatment of climacteric complaints and the prevention of osteoporosis. Tibolone is a selective tissue oestrogenic activity regulator (STEAR). Tibolone substitutes for the loss of oestrogen production in postmenopausal women, and alleviates menopausal symptoms. Tibolone prevents bone loss following menopause or ovariectomy.
  2. Following oral administration, tibolone is metabolized to three primary active agents: 3 α -hydroxy-tibolone; 3 β -hydroxy-tibolone; and Δ 4 -tibolone. The 3 α - and 3 β -OH-metabolites of tibolone bind solely to the estrogen receptors, resulting in estrogenic effects on the bone and vaginal tissue. The Δ 4 -isomer has affinity for the progesterone and androgen receptors. In endometrial tissue, the Δ 4 -isomer functions as a progestagen, whereas in the brain and liver it has androgenic effects. Bone Tibolone has a direct oestrogenic effect on bone, decreasing bone resorption and maintaining bone mass. Tibolone significantly improves bone mineral density (BMD), especially trabecular BMD. Endometrium Tibolone acts as an antioestrogen in the endometrium. Tibolone does not stimulate endometrial proliferation, and hence is associated with less vaginal bleeding (and less irregular bleeds) Mood and libido Tibolone may act indirectly to decrease sex hormone-binding globulin (SHBG) concentrations and thereby increase the availability of testosterone. Tibolone may therefore improve sexual function. Tibolone improves libido, possibly via weak androgenic activity in the central nervous system. Breast Tibolone and the Δ 4 -isomer have been shown to behave as progestins, decreasing the proliferation rate. Tibolone and its Δ 4 -isomer also stimulate apoptosis in breast cells. Tibolone also interferes with the metabolic pathways of estrogens in human breast cells. It strongly inhibits sulfatase activity and weakly inhibits 17 β -hydroxysteroid dehydrogenase activity, which result in blocking the conversion of estrone sulfate to estradiol; thereby encouraging the formation of biologically inactive oestrogen sulphate. Cardiovascular Effects Tibolone significantly reduces lipoprotein(a) and triglycerides, and modestly reduces low-density lipoprotein cholesterol. Other benefits include include stimulation of blood flow and vessel relaxation and an increase in fibrinolysis.
  3. NOTES This randomized, open-label, parallel-group study compared the effect of continuous combined conjugated equine estrogens and medroxyprogesterone acetate (CEE/MPA) vs. tibolone on symptom control, vaginal bleeding, lipid profiles and tolerability. Apparently healthy postmenopausal women were randomly assigned CEE/MPA (0.625 mg/5.0 mg) or tibolone 2.5 mg daily for 13 treatment cycles, each of 28 days. In total 85 women received at least one dose of study medication, and of these 76 (89.4%) women completed the study (n = 40, CEE/MPA; n = 36, tibolone). The incidence of menopausal and urogenital symptoms decreased significantly over time in both treatment groups compared to baseline. Significant differences in symptom control (other than hot flushes) were observed between treatment groups in different cycles and for different symptoms, but no consistent or clinically significant trends were observed. No statistically significant differences in the incidence of vaginal bleeding were observed between treatment groups after cycle 4. Women treated with CEE/MPA or tibolone showed significant improvement of menopausal and urogenital symptoms, and sexual well being and had similar vaginal bleeding patterns after four cycles of therapy. CEE/MPA and tibolone each induced a different mix of changes in the circulating lipid profile. Reference 1. Baracat E. C., Barbosa I. C., Giordano M. G., Haidar M. A., Marinho R. M., Menegocci J.C., Morais K. M., Tomaz G. Wehba S. .A randomized, open-label study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone: effects on symptom control, bleeding pattern, lipid profile and Tolerability; Climacteric 2002; 5: 60-69.